- Home
- APRE vs LPCN Comparison
APRE vs LPCN Comparison
Compare APRE & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- LPCN
- Stock Information
- Founded
- APRE 2006
- LPCN 1997
- Country
- APRE United States
- LPCN United States
- Employees
- APRE N/A
- LPCN N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- LPCN Health Care
- Exchange
- APRE Nasdaq
- LPCN Nasdaq
- Market Cap
- APRE 21.2M
- LPCN 19.4M
- IPO Year
- APRE 2019
- LPCN N/A
- Fundamental
- Price
- APRE $2.62
- LPCN $3.38
- Analyst Decision
- APRE Strong Buy
- LPCN Strong Buy
- Analyst Count
- APRE 2
- LPCN 1
- Target Price
- APRE $15.50
- LPCN $10.00
- AVG Volume (30 Days)
- APRE 35.9K
- LPCN 33.0K
- Earning Date
- APRE 03-25-2025
- LPCN 03-06-2025
- Dividend Yield
- APRE N/A
- LPCN N/A
- EPS Growth
- APRE N/A
- LPCN N/A
- EPS
- APRE N/A
- LPCN N/A
- Revenue
- APRE $1,310,839.00
- LPCN $7,922,926.00
- Revenue This Year
- APRE $134.21
- LPCN N/A
- Revenue Next Year
- APRE N/A
- LPCN N/A
- P/E Ratio
- APRE N/A
- LPCN N/A
- Revenue Growth
- APRE 130.31
- LPCN N/A
- 52 Week Low
- APRE $2.15
- LPCN $3.20
- 52 Week High
- APRE $8.85
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- APRE 30.05
- LPCN 30.99
- Support Level
- APRE $2.59
- LPCN $3.42
- Resistance Level
- APRE $3.72
- LPCN $3.62
- Average True Range (ATR)
- APRE 0.35
- LPCN 0.26
- MACD
- APRE -0.13
- LPCN -0.02
- Stochastic Oscillator
- APRE 1.41
- LPCN 1.61
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.